Profile data is unavailable for this security.
About the company
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
- Revenue in INR (TTM)50.41bn
- Net income in INR1.61bn
- Incorporated2005
- Employees5.75k
- LocationLaurus Labs LtdSerene Chambers, Road No 7, BanjarahillsHYDERABAD 500034IndiaIND
- Phone+91 4 039804333
- Fax+91 4 066594320
- Websitehttp://www.lauruslabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eris Lifesciences Ltd | 20.09bn | 3.92bn | 124.64bn | 3.55k | 31.83 | 4.82 | 21.50 | 6.20 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Concord Biotech Ltd | 10.17bn | 3.08bn | 153.11bn | -- | 49.71 | 10.03 | 42.33 | 15.06 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | -- | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Astrazeneca Pharma India Ltd | 12.96bn | 1.62bn | 154.48bn | 947.00 | 95.65 | 21.70 | 87.55 | 11.92 | 64.60 | 64.60 | 518.18 | 284.77 | 1.26 | 2.84 | 9.94 | -- | 15.66 | 11.78 | 24.44 | 19.62 | 54.11 | 56.40 | 12.47 | 10.27 | 1.97 | 141.18 | 0.0064 | 27.16 | 29.17 | 12.21 | 62.66 | 24.29 | -10.45 | -- |
Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 157.14bn | 1.17k | 52.27 | 7.66 | 44.30 | 14.95 | 11.81 | 11.81 | 41.36 | 80.56 | 0.4983 | 1.64 | 8.60 | -- | 14.23 | 23.17 | 15.19 | 26.20 | 57.59 | 58.56 | 28.56 | 33.21 | 9.65 | 66.88 | 0.0307 | -- | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Piramal Enterprises Ltd | 80.27bn | -16.84bn | 177.69bn | 12.22k | -- | 0.6691 | -- | 2.21 | -76.51 | -76.51 | 345.53 | 1,187.94 | 0.0965 | -- | 497.33 | -- | -2.02 | 2.57 | -2.05 | 3.16 | 45.17 | 81.98 | -20.97 | 21.59 | -- | -0.0035 | 0.6686 | 26.39 | -3.80 | -7.55 | -116.89 | -- | 12.91 | -18.22 |
Natco Pharma Ltd. | 39.99bn | 13.88bn | 178.69bn | 3.98k | 12.91 | 3.05 | 11.34 | 4.47 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 181.45bn | 14.59k | 29.45 | 3.77 | 20.40 | 2.91 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | -- | 9.77 | 10.82 | 12.94 | 14.38 | 72.46 | 67.67 | 9.90 | 12.58 | 0.9863 | 11.76 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Piramal Pharma Ltd | 81.71bn | 178.20m | 195.55bn | 6.30k | 2,467.50 | 2.48 | 25.78 | 2.39 | 0.06 | 0.06 | 65.09 | 59.80 | 0.5478 | 1.53 | 4.15 | -- | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Sanofi India Ltd | 28.47bn | 5.49bn | 198.69bn | 2.17k | 36.19 | -- | 33.73 | 6.98 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Pfizer Ltd | 21.93bn | 5.51bn | 210.89bn | 1.70k | 38.25 | 5.87 | 34.37 | 9.62 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Laurus Labs Ltd | 50.41bn | 1.61bn | 225.87bn | 5.75k | 141.06 | 5.49 | 40.86 | 4.48 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Syngene International Ltd | 34.89bn | 5.10bn | 269.71bn | 6.85k | 53.00 | 6.33 | 28.82 | 7.73 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 275.00bn | 5.10k | 50.44 | 9.41 | 39.80 | 7.89 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
IPCA Laboratories Ltd | 77.07bn | 5.47bn | 292.31bn | 16.17k | 53.39 | 4.62 | 32.97 | 3.79 | 21.58 | 21.58 | 303.89 | 249.59 | 0.7814 | 1.22 | 5.76 | -- | 5.37 | 10.33 | 7.51 | 13.52 | 66.58 | 60.93 | 6.87 | 12.25 | 1.30 | 12.59 | 0.1569 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
Ajanta Pharma Ltd | 42.09bn | 8.16bn | 293.78bn | 7.71k | 36.01 | 8.24 | 30.87 | 6.98 | 64.79 | 64.79 | 334.10 | 283.32 | 0.9034 | 1.30 | 3.65 | -- | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.51 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 15.18 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
Gland Pharma Ltd | 56.65bn | 7.72bn | 303.09bn | 4.59k | 39.24 | 3.47 | 27.13 | 5.35 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 59.23m | 10.99% |
Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Apr 2024 | 21.97m | 4.08% |
The Vanguard Group, Inc.as of 09 May 2024 | 14.70m | 2.73% |
Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 14.56m | 2.70% |
Barclays Wealth Trustees (India) Pvt Ltd.as of 30 Sep 2023 | 7.30m | 1.35% |
BlackRock Fund Advisorsas of 09 May 2024 | 4.86m | 0.90% |
Dimensional Fund Advisors LPas of 09 May 2024 | 4.18m | 0.78% |
SBI Funds Management Ltd.as of 15 May 2024 | 4.13m | 0.77% |
FIL Investment Management (Singapore) Ltd.as of 30 Apr 2024 | 3.63m | 0.67% |
Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 3.52m | 0.65% |